Get started
IMMUNOVIA AB NPVIMMUNOVIA AB NPVIMMUNOVIA AB NPV

IMMUNOVIA AB NPV

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

0G8X chart


Full chart

0G8X upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪105.45 M‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.2300 SEK
Net income (FY)
‪−76.54 M‬ SEK
Revenue (FY)
‪931.00 K‬ SEK
Shares float
‪297.74 M‬
Beta (1Y)
−0.95

Employees


Employees (FY)
9
Change (1Y)
−2 −18.18%
Revenue / Employee (1Y)
‪103.44 K‬ SEK
Net income / Employee (1Y)
‪−8.50 M‬ SEK

About IMMUNOVIA AB


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jeff Borcherding
Website
immunovia.se
Headquarters
Lund
Founded
2007
ISIN
SE0006091997
FIGI
BBG00JWMYYW7
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0G8X news



Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as 0G8X.

Frequently Asked Questions


The current price of 0G8X is 0.3390 SEK — it has increased by 5.72% in the past 24 hours. Watch IMMUNOVIA AB NPV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange IMMUNOVIA AB NPV stocks are traded under the ticker 0G8X.
0G8X stock has risen by 54.36% compared to the previous week, the month change is a 57.87% rise, over the last year IMMUNOVIA AB NPV has showed a −75.79% decrease.
0G8X reached its all-time high on Oct 12, 2020 with the price of 270.9930 SEK, and its all-time low was 0.2620 SEK and was reached on Apr 7, 2025. View more price dynamics on 0G8X chart.
See other stocks reaching their highest and lowest prices.
0G8X stock is 22.71% volatile and has beta coefficient of −0.95. Track IMMUNOVIA AB NPV stock price on the chart and check out the list of the most volatile stocks — is IMMUNOVIA AB NPV there?
Today IMMUNOVIA AB NPV has the market capitalization of ‪105.45 M‬, it has increased by 42.82% over the last week.
Yes, you can track IMMUNOVIA AB NPV financials in yearly and quarterly reports right on TradingView.
IMMUNOVIA AB NPV is going to release the next earnings report on Aug 21, 2025. Keep track of upcoming events with our Earnings Calendar.
IMMUNOVIA AB NPV revenue for the last quarter amounts to 0.00 SEK, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0G8X net income for the last quarter is ‪−57.79 M‬ SEK, while the quarter before that showed ‪3.07 M‬ SEK of net income which accounts for ‪−1.98 K‬% change. Track more IMMUNOVIA AB NPV financial stats to get the full picture.
No, 0G8X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 24, 2025, the company has 9 employees. See our rating of the largest employees — is IMMUNOVIA AB NPV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IMMUNOVIA AB NPV EBITDA is ‪−89.13 M‬ SEK, and current EBITDA margin is ‪−10.05 K‬%. See more stats in IMMUNOVIA AB NPV financial statements.
Like other stocks, 0G8X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOVIA AB NPV stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNOVIA AB NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNOVIA AB NPV stock shows the sell signal. See more of IMMUNOVIA AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.